|NASDAQ: AZYO||Healthcare / Medical Devices & Instruments / USA|
|1.47||+0.0700||+5.00%||Vol 839.77K||1Y Perf -71.94%|
|Mar 24th, 2023 16:00 DELAYED|
|- -||0.02 1.35%|
|Target Price||11.38||Analyst Rating||Strong Buy 1.00|
|Potential %||674.15||Finscreener Ranking||★★+ 47.00|
|Insiders Trans % 3/6/12 mo.||-/-100/-||Value Ranking||★ 39.79|
|Insiders Value % 3/6/12 mo.||-/-/100||Growth Ranking||★★ 44.64|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/89||Income Ranking||— -|
|Price Range Ratio 52W %||4.68||Earnings Rating||—|
|Market Cap||23.70M||Earnings Date||8th May 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th May 2023|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.02M|
|Avg. Monthly Volume||519.25K|
|Avg. Quarterly Volume||194.28K|
Aziyo Biologics Inc. (NASDAQ: AZYO) stock closed at 1.47 per share at the end of the most recent trading day (a 5% change compared to the prior day closing price) with a volume of 839.77K shares and market capitalization of 23.70M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 163 people. Aziyo Biologics Inc. CEO is Ronald K. Lloyd.
The one-year performance of Aziyo Biologics Inc. stock is -71.94%, while year-to-date (YTD) performance is -65.41%. AZYO stock has a five-year performance of %. Its 52-week range is between 1.1 and 9.01, which gives AZYO stock a 52-week price range ratio of 4.68%
Aziyo Biologics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 13.34, a price-to-sale (PS) ratio of 1.23, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -60.40%, a ROC of -107.60% and a ROE of 2 588.31%. The company’s profit margin is -75.18%, its EBITDA margin is -58.50%, and its revenue ttm is $36.52 Million , which makes it $3.09 revenue per share.
Of the last four earnings reports from Aziyo Biologics Inc., there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Aziyo Biologics Inc.’s next earnings report date is 08th May 2023.
The consensus rating of Wall Street analysts for Aziyo Biologics Inc. is Strong Buy (1), with a target price of $11.38, which is +674.15% compared to the current price. The earnings rating for Aziyo Biologics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aziyo Biologics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aziyo Biologics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.94, ATR14 : 0.46, CCI20 : -131.64, Chaikin Money Flow : -0.26, MACD : -0.74, Money Flow Index : 52.07, ROC : -67.33, RSI : 22.03, STOCH (14,3) : 10.57, STOCH RSI : 0.19, UO : 25.94, Williams %R : -89.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aziyo Biologics Inc. in the last 12-months were: Brigid A. Makes (Buy at a value of $7 300), David Colpman (Buy at a value of $12 082), Jerome Riebman (Option Excercise at a value of $0), Matthew B. Ferguson (Buy at a value of $126 400), Matthew B. Ferguson (Option Excercise at a value of $0), Peter G. Edwards (Option Excercise at a value of $0), Thomas Englese (Option Excercise at a value of $0), Thomas Englese (Sold 289 shares of value $1 243 )
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Strong Buy||Strong Buy||Strong Buy|
Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
CEO: Ronald K. Lloyd
Telephone: +1 240 247-1170
Address: 12510 Prosperity Drive, Silver Spring 20904, MD, US
Number of employees: 163
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.